{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:40:50Z","timestamp":1776418850209,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtocrr.2025.100802","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T16:31:50Z","timestamp":1739377910000},"page":"100802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-1573","authenticated-orcid":false,"given":"Abhenil","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Everest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devalben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna J.","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Catherine","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemah","family":"Zaeimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaleeq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karmugi","family":"Balaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Garcia Pardo","family":"de Santayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"De Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100802_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/mco.2022.2522","article-title":"Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (review)","volume":"16","author":"Rijavec","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.20315","article-title":"Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation","volume":"101","author":"Hollen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2025.100802_bib3","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2004.09.147","article-title":"Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module","volume":"22","author":"Nowak","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib4","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/03007995.2016.1226165","article-title":"Symptom burden in mesothelioma patients admitted to home palliative care","volume":"32","author":"Mercadante","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtocrr.2025.100802_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"suppl 17","key":"10.1016\/j.jtocrr.2025.100802_bib6","article-title":"IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and IFCT trial","volume":"41","author":"Chu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2005.07.025","article-title":"Does a patient\u2019s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?","volume":"42","author":"Efficace","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100802_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib9","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2010.33.4631","article-title":"Relationship between deficits in overall quality of life and non-small-cell lung cancer survival","volume":"30","author":"Sloan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0825859720948975","article-title":"Symptom burden and unmet needs in malignant pleural mesothelioma: exploratory analyses from the RESPECT-Meso study","volume":"36","author":"Hoon","year":"2021","journal-title":"J Palliat Care"},{"key":"10.1016\/j.jtocrr.2025.100802_bib11","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","article-title":"Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 Phase III trial","volume":"25","author":"Eberst","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100802_bib12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/bjc.2015.77","article-title":"The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial","volume":"112","author":"Arnold","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100802_bib14","first-page":"4123","article-title":"Symptom assessment for patients with non-small cell lung cancer scheduled for chemotherapy","volume":"36","author":"Silvoniemi","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtocrr.2025.100802_bib15","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.3747\/co.26.5297","article-title":"Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites","volume":"26","author":"Moskovitz","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib16","article-title":"Using patient-reported outcomes to describe the patient experience on phase I clinical trials","volume":"4","author":"Sedhom","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jtocrr.2025.100802_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jpainsymman.2018.05.017","article-title":"Comparison of EORTC QLQ-C30 and PRO-CTCAETM questionnaires on six symptom items","volume":"56","author":"Taarnh\u00f8j","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jtocrr.2025.100802_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","article-title":"Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol","volume":"22","author":"Stolk","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jtocrr.2025.100802_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"key":"10.1016\/j.jtocrr.2025.100802_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0345-9","article-title":"Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity","volume":"6","author":"Smith","year":"2016","journal-title":"Behav Med Pract Policy Res"},{"key":"10.1016\/j.jtocrr.2025.100802_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jtocrr.2025.100802_bib22","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.cllc.2021.08.003","article-title":"Treatment patterns and outcomes of patients with advanced pleural mesothelioma at an academic referral centre","volume":"23","author":"Schmid","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100802_bib23","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2025.100802_bib24","first-page":"69","article-title":"Statistics corner: a guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"10.1016\/j.jtocrr.2025.100802_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00520-012-1569-6","article-title":"Health-related quality of life and inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Kao","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtocrr.2025.100802_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton symptom assessment system 25 years later: past, present, and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jtocrr.2025.100802_bib27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00520-017-3887-1","article-title":"Utility of the revised Edmonton Symptom Assessment System (ESAS-r) and the Patient-Reported Functional Status (PRFS) in lung cancer patients","volume":"26","author":"Yogananda","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtocrr.2025.100802_bib28","first-page":"e196","article-title":"Cancer patients? Willingness to routinely complete the EQ-5D instrument at clinic visits","volume":"23","author":"Naik","year":"2016","journal-title":"J Popul Ther Clin Pharmacol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:04:05Z","timestamp":1748966645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666364325000189"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100802","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100802"}}